For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week. Currently, patients are treated with injections of asfotase alfa, a mineral-targeted form of the missing enzyme called tissue-nonspecific alkaline phosphatase (TNAP).